Advancing Cardiovascular and NASH Opportunities

Corporate Presentation June 2017

Safe Harbor Statement

2

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, anyinformation contained in this presentation may be a forward‐looking statement that reflects the Company’s current views aboutfuture events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or theCompany’s actual activities or results to differ significantly from those expressed in any forward‐looking statement. In some cases,you can identify forward‐looking statements by terminology such as “may”, “will”, “could”, “would”, “should”, “plan”, “predict”,“potential”, “project”, “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “believe,” and similar expressions andvariations thereof. Forward‐looking statements may include statements regarding the Company’s business strategy, market size,potential growth opportunities, capital requirements and use of proceeds, clinical development activities, the timing and resultsof clinical trials, regulatory submissions, potential regulatory approval and commercialization of the product candidate. Althoughthe Company believes that the expectations reflected in such forward‐looking statements are reasonable, the Company cannotguarantee future events, results, actions, levels of activity, performance or achievements. These forward‐looking statements aresubject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in ourfilings with the SEC. These forward‐looking statements speak only as of the date of this presentation and the Company undertakesno obligation to revise or update any forward‐looking statements to reflect events or circumstances after the date hereof.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to marketshares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned notto give undue weight to such estimates.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use shouldnot be construed as an endorsement of such products.

Cardiovascular Disease: A Major Global Health Problem

3

• #1 Cause of death (~1 in 3 people)

• Rising prevalence due to obesity and type 2 diabetes

• Elevated cholesterol (LDL-C) is #1 modifiable risk factor

• New therapies beyond statins are needed

World Health OrganizationAmerican Heart Association Report, 2016

Dyslipidemia is an Attractive Therapeutic Area

4

Acceptable Surrogate Endpoints

New Evidence Further Supports LDL Hypothesis

Few Late Stage Drugs in Development

Growing, Large Unmet Medical Need

Gemcabene is the Only Late Stage Asset in Development Targeting the Spectrum of Dyslipidemias

Large Markets for Gemcabene – 20 Million Patients in U.S.

5

~6M NASH(2)

(NAFLD est. 60M+)

Ad

dre

ssab

le M

arke

t(P

atie

nts

)

~1M FH(1)

(HeFH /HoFH)

~3M SHTG(1)

(Severe Hypertriglyceridemia)

~10M ASCVD(1)

(Mixed Dyslipidemia and Non-Familial

Hypercholesterolemia)

D I A B E S I T YCholesterol InflammationTriglycerides

Mar

ket

Size

($

)

Dyslipidemia NASH Total Market

~$13B(3) ~$20B(4)

~20MPatients

~$33Bby 2025

1) Company estimate based on DRG Market Data, NHANES and FH Foundation.2) The National Institute of Diabetes and Digestive and Kidney Diseases, 20163) Decision Resources Group 2015 report4) Transparency Market Research (April 2016)

Our Solution: Gemcabene

Oral tablet

Once-daily dosing

Cost effective (allows competitive pricing)

Unique ability to lower LDL, TG, and hsCRP

Promising safety and tolerability profile

Lack of DDI with statins

6

Out-licensed from Pfizer • Conducted 18 clinical trials (11 Phase 1 and 7 Phase 2)• Observed to be safe and efficacious in 895 patients

Gemcabene Increases Clearance

Gemcabene Molecule

• Plasma half life of 32 to 41 hours• Liver is target organ• Gemcabene is the active compound• Renal elimination

*Potential molecular targets in the liver (ApoC-III, ACC)

Gemcabene Reduces Production

Gemcabene Novel Mechanism of Action in Liver

7

Triglyceride PathwayCholesterol Pathway

ApoC–III

VLDL

LDL

Acetyl-CoA

HMG-CoA Malonyl-CoA

Fatty-acyl-CoA

Cholesterol Triglycerides

VLDL Remnant

Acetyl-CoA carboxylase (ACC)*

Mevalonate

Acetoacetyl-CoA

VLDL

~

ApoC–III* ~LDL

TG

ApoE

ApoE

• Cholesterol production decreased• Triglyceride synthesis lowered

• Clears VLDL efficiently via reduction in ApoC-III followed by rapid uptake by the remnant receptor

Protective of the Downstream Effects of Fatty Liver Disease

Reducing the Burden of Atherosclerosis

Gemcabene’s Pleiotropic Mechanisms of ActionFirst-in-class Drug Hits Multiple Established Targets Lowering LDL-C, TG, and hsCRP

NASH

Inflammation

↓ HsCRP

↓ IL-6 & IL-1β

↓ CCR2 & CCR5

Glucose Metabolism

↑ Insulin Sensitivity

8

Lipid Metabolism

↓ LDL-C

↓ TGo ACC1

↓ VLDL oApoC-III

↑ HDL-C

Atherosclerosis

Indication Phase 1 Phase 2a Phase 2b Phase 3 NDA Anticipated Milestones

Homozygous Familial Hypercholesterolemia(HoFH)

COBALT-1 Phase 2b trial (n=8) enrollment completed; interim data January 30, 2017; top-line data expected end of June 2017

Hypercholesterolemia –Heterozygous Familial Hypercholesterolemia (HeFH) ROYAL-1 Phase 2b trial (n=105) enrollment

completed ahead of schedule; top-line data expected in 3Q 2017Hypercholesterolemia –

Atherosclerotic Cardiovascular Disease (ASCVD)

Severe Hypertriglyceridemia(SHTG)

INDIGO-1 Phase 2b trial (n=90) enrollment ongoing; top-line data expected in 1Q 2018

Non-alcoholic Steatohepatitis (NASH) / Non-alcoholic Fatty Liver Disease (NAFLD)

Initiate proof-of-concept clinical programfor NAFLD/NASH in 2H 2017

Gemcabene Pipeline and Clinical PlansThree CV Phase 2b Trials and One NASH Phase 2 Trial for Gemcabene

9

LDL-Receptor Deficient Mice Model COBALT-1 Phase 2b Interim Results

10

Gemcabene Lowers LDL-C in HOFHCompelling Preclinical Data & Interim Phase 2b Clinical Results COBALT-1

28% LDL-C Lowering First 2 HoFH Patients

(reported January 2017)

Gemcabene Reduces LDL-C in HoFH Mice Model

Charles Bisgaier et al, US Patent Application No.: US 2002/0103252 A1 Aug.1,2002

Preclinical Data Supports Potential for Meaningful Clinical Efficacy and

Complementary MOA

11

Prior Phase 2 Study Supports Rationale for ROYAL-1 Trial

Gemcabene Showed Meaningful Efficacy in Hypercholesterolemic Patients Taking Statins

Median Percent Change from Baseline at Week 8 in Patients with Hypercholesterolemia on Background Stable Statin Therapy

Phase 2 Trial (1027-018)

Journal of Clinical Lipidology (Stein et al, 2016)

30% LDL-C Lowering and 50% hsCRP Lowering on Top of All Doses of Statins

12

Gemcabene Showed Meaningful Efficacy in Severe Hypertriglyceridemia

Phase 2 Trial 1027-004 Results

Note: Although patients treated with gemcabene at 600 mg and 900 mg were observed to have lower triglycerides, the lowering effect was not significant when compared to placebo.

Prior Phase 2 Study Supports Rationale for INDIGO-1 Trial

TG ≥ 200, GEM Lowers TG 39%; TG ≥ 500, GEM Lowers TG 60%

13

Statins (e.g. Lipitor, Crestor, Zocor)

Doubling statin dose only adds 4%-6% efficacy with increased

toxicities

Ezetimibe (Zetia)

Juxtapid (HoFH)

GemcabeneETC-1002

CETPi

Repatha

Praluent

Kynamro (HoFH)

MDCO PCSK9

Gemcabene: Complementary Add-on to Lipid-Lowering Drugs

1st Line Oral 2nd Line Oral 3rd Line Injectables

Gemcabene Is Well-Differentiated in Dyslipidemia

Gemcabene(Phase 2b)

Dyslipidemia Therapeutics

Statin Class

Approved

PCSK9 Antibodies

Approved

MDCOPCSK9siP3 ready

ESPRETC-1002P3 started

Fibrates

Approved

Fish Oil

Approved

IonisVolanesorsen

P3 (FCS, FPL)

MOAApoC-III, also ACC

inhibitor

HMG-CoA reductase inhibitor

PCSK9 inhibitors

RNAiACL

inhibitorPPAR-αagonist

Omega-3APOC-III

antisense inhibitor

Once-Daily Oral × × O ×

Low Cost × × ×

↓ LDL × × ×

↓ TG × × ×

↓ hsCRP × × × O ×

Combine Safely w/ Statins × × unknown

Sources: Gemphire Estimates, ClinicalTrials.gov, Analyst Research Reports, Company Websites and Presentations

14

Yes

× No

O Somewhat

Not Applicable

15

Liver Disease (NAFLD / NASH) - Next Global EpidemicPrevalence Expanding Due to Diabetes and Obesity

• Non-alcoholic fatty liver disease (NAFLD) progresses to non-alcoholic steatohepatitis (NASH)

• NASH is termed a Silent Killer

– Minimal symptoms at early stage– Over time includes fatigue, weight loss, and weakness

• NASH characterized by excessive fat accumulation, inflammation, ballooning and fibrosis in the liver

• Rising prevalence of diabetes and obesity contribute to a rapid rise in the prevalence of NAFLD (60M+ in US ) and NASH (~6M in US)

• NASH is passing Hepatitis C as the leading cause of liver transplant

• No approved therapies to treat NASH

16

Mechanism of Action

• Pleiotropic effects on fat, lipids, and inflammation

PreclinicalData

• Demonstrated reduction in lipogenesis and hepatic fat content• Positive results in proof-of-concept NASH preclinical study STAM model

ClinicalData

• Reduction of atherogenic lipid parameters (e.g. TG, LDL-C, apoB, non-HDL-C)• Lowered plasma TG (via APOC-III) • Lowered markers of inflammation (e.g., hsCRP)• Improved glucose disposal rate, suggesting improved insulin sensitivity

SafetyData

• No liver or muscle toxicities with over 895 patients treated• No DDIs with statins• No cumulative toxicities in 52 week monkey studies

Rationale for Gemcabene in NASH

17

Positive Proof-of-Concept Preclinical NASH Data Gemcabene Improves NALFD Activity and Fibrosis Scores in STAM™ Model

1) NAFLD Activity Score (NAS) composited comprised of steatosis, inflammation, & ballooning2) This comparison is for illustrative purposes as these were separate studies3) E. Lefebre et al., The Liver Meeting AASLD, Abstract 30 presentation, 2013 4) Enanta Pharmaceuticals Company Presentation, 2016

Tobira’s CVC (CCR2/CCR5 inhibitor):• ~23% to 30% improvement in NAS score• ~60% reduction in fibrosis

Intercept’s OCA (FXR agonist):• ~23% improvement in NAS score

Enanta’s EDP-305 (FXR agonist):• ~30% improvement in NAS score

STAM Model Data Comparable to Other Late Stage Compounds2,3,4

NAS Score1 25% to 48%

Full details available upon publication

Full details available upon publication

Fibrosis ~33%

Gemcabene

18

Favorable Biomarkers in STAM™ Model Gemcabene Demonstrates Significant Reductions in Lipid / Inflammation Markers

Select Hepatic Gene Expression and Plasma Markers

CategoryGene Expression/Plasma Markers

Vehicle in NASH Gemcabene(100 mg/kg)

(vs Vehicle in Normal) (vs Vehicle in NASH)

Inflammation

CRP -- ▼

CCR2 ▲ ▼

CCR5 ▲ ▼

TNF-α ▲ ▼

MCP-1 ▲ ▼

MIP-1β ▲ ▼

NF-kB ▲ ▼

Lipid Metabolism

ApoC-III ▼ ▼

SULF-2 ▲ ▼

ADH4 -- ▼

ACC1 -- ▼

Full details available upon publication

-- No significant difference ▲ significant increase ▼ significant decrease Key:

Gemcabene Is Differentiated in NASH

Gemcabene(Phase 2b)

NASH Therapeutics

ICPT OCA(P3,

Approved PBC)

GenfitElafibranor

(P3)

GileadGS-4997(P3 ready)

Nimbus/ Gilead

GS-0976(P2)

TobiraCVC

(P3 ready)

ConatusEmricasan

(P2)

MOAApoC-III, also ACC

inhibitorFXR agonist

PPAR-α & δagonist

ASK-1 inhibitor

ACC Inhibitor

CCR2/CCR5 inhibitor

Caspase Inhibitor

Targets Liver- and Cardio-Protection × × × × × ×

NAS Score Reduction Preclinical

Anti-Fibrotic Effect Unknown

↓ Fat / TG × ×

↓ hsCRP unknown × unknown

Combine Safely w/ Statins O unknown unknown unknown × unknown

Sources: Gemphire Estimates, Data on File, ClinicalTrials.gov, Analyst Research Reports, Company Websites and Presentations

19

Yes

× No

O Somewhat

Not Applicable

Headline Phase Upfront (M) Total (M)

Phase 2 $600 $1,700

Phase 1 $400 $1,200

Phase 2 $50$700

w/ tiered double-digit royalties

Phase 1/2

$175 (/equity)

$1,600

Phase 2 $300 $1,550

Recent Attractive Dyslipidemia and NASH M&A Deals

20

Dys

lipid

emia

NA

SH

Sources: Marketwatch, Genetic Engineering & Biotechnology News, FierceBiotech, BioWorld

Steve Gullans, PhDInterim Chief Executive Officer

Charles Bisgaier, PhDChief Scientific Officer & Cofounder

Jeff Mathiesen, CPAChief Financial Officer

Lee Golden, MDChief Medical Officer

Seth Reno, MBAChief Commercial Officer

Daniela Oniciu, PhDVP, Manufacturing & Preclinical R&D

Rebecca Bakker-Arkema, RPh, MS, FAHAVP, Drug & Clinical Development

Liz MassonVP, Clinical Operations

Prior Marketed Products Experience Prior Pipeline Development Experience

CER-001 and CER 209(Cerenis)

ETC-1002 and ETC-216(Esperion)

PNT-2258(ProNAi)

ACP-501(AstraZeneca/AlphaCore)

Proven and Successful Management Team

21

Gemphire IPO on NASDAQ as GEMP in August 2016

NASDAQ Global Market

Symbol GEMP

Market Cap1 ~$114M

Price Per Share1 $10.76/share

Shares Outstanding2 10.6M

Cash Position at 3/31/17 $29M

22

GEMP Analyst Coverage

Canaccord Genuity Inc.John Newman, Ph.D.

Jefferies LLCMatthew J. Andrews

Laidlaw & CompanyFrank Brisebois

LifeSci CapitalPatrick Dolezal

Piper Jaffray & CoJoshua E. Schimmer, MD

RBC Capital MarketsAdnan Butt

Institutional Ownership Shares Held3

At March 31, 2017

Cormorant Funds 953K shares (9%)

Excel Venture Management 858K shares (8%)

Pfizer 675K shares (6%)

Adage Capital Management 620K shares (6%)

Highland Healthcare Funds 317K shares (3%)

Sigma Emerging Markets 303K shares (3%)

1 At June 1, 2017; 2 Fully Diluted Shares Outstanding = 13.9M

3 Percentage Ownership Calculated on Shares Outstanding

Key Catalysts in 2017 and 2018Near Term Transformational Opportunity

23

Top-Line Data in All 3 Dyslipidemia Trials

1H 20182H 2017

□ Presentation(s) at industry meetings (if accepted)

□ Consider partnership opportunities for Phase 3 programs

□ Complete in-life 2 year rodent carcinogenicity studies

□ Presentation(s) at industry meetings (if accepted)

Submit NASH preclinical abstracts and manuscripts

Repatha reported positive FOURIER CVOT data

□ INDIGO-1 (SHTG) Readout

□ EOP2 Meetings

□ ROYAL-1 (HeFH/ASCVD) Readout

□ Initiate NAFLD/ NASH Clinical Program

COBALT-1 (HoFH) Interim Data

□ COBALT-1 (HoFH) Readout

1H 2017

Other Potential Catalysts

Gemphire Corporate Summary

24

• Gemcabene – Novel compound and MOA, licensed from Pfizer

• Scarce and differentiated late-stage cardiovascular asset

• Safe add-on therapy to statins

• Targeting substantial market opportunities – 20 million U.S. patients

• Several near term catalysts

• Recently public (NASDAQ:GEMP), strong financial position

• Proven leadership team

APPENDIX

25

Gemphire Corporate Summary

26

• Gemcabene – Novel compound and MOA, licensed from Pfizer

o Oral, once-daily, small molecule

o Novel pleiotropic mechanism: observed to significantly lower cholesterol, fat, and inflammation

o Safety and efficacy data from 895 subjects across 18 clinical trials (11 Phase 1 and 7 Phase 2)

• Safe add-on therapy to statins

o No DDI with statins while also lowering LDL-C by more than 20% in Phase 2 trial

• Targeting substantial market opportunities – 20 million U.S. patients

o Phase 2b Cardiovascular trials ongoing (HoFH, HeFH / ASCVD, SHTG)

o Initiating NAFLD/NASH clinical program in 2H 2017

• Several near term catalysts

o Three Phase 2b Cardiovascular trials scheduled to read out over the next several quarters

• Recently public (NASDAQ:GEMP), strong financial position

o Cash $29 million at March 31, 2017

o Blue chip investors: Cormorant, Excel VM, Adage, Highland Capital, others

• Proven leadership team

o Cardiovascular drug development, partnering and commercial leadership at Pfizer, Esperion, AstraZeneca and others

Gemcabene Protection with Market Exclusivity and Patents

27

COBALT(HoFH)

ROYAL(HeFH/ASCVD)

INDIGO(SHTG)

AZURE(NASH)

Formulation Composition of Matter US Patent #6,861,555Expiry 2021 (before patent term extensions)

SHTG: Method for Treating PancreatitisUS Patent #8,846,761 Expiry 2032

Add on Stable Statin Therapy: Methods for Reducing CV RiskUS Application #14/370,722Expiry 2033 if Issued

Treatment of Mixed DyslipidemiaUS Provisional Application #15/424,620Expiry 2037 if Issued

Treatment of NASHUS Provisional Application #15/416,911Expiry 2037 if Issued

Fixed Dose Combination FormulationsUS Provisional Application #62/252,147Expiry 2036 if Issued

Processes & Intermediates for ManufacturingUS Application #14/942,765 Expiry 2035 if Issued

POTENTIAL FOR MARKET EXCLUSIVITY (New Molecular Entity)• US (5 years or more); U.S. HoFH Orphan (7 years); Europe (up to 10 years); Japan (up to 10 years)

EXPANDING INTELLECTUAL PROPERTY ESTATE• In total, 49 issued patents (4 in US) and 24 pending applications (8 in US)

• LDL-C ~30%• TG ~40%• hsCRP ~40%

Note: Percentages (Mean and Median - LDL-C, Median - hsCRP, TG) have been demonstrated across multiple clinical studies.A decrease in CRP (an earlier clinical assay) correlates with a decrease in hsCRP (the current CV risk assay).

A NOVEL, COST-EFFECTIVE, ONCE-DAILY ORAL THERAPY

Gemcabene Differentiated Product Profile

28

Significant Lipid-Lowering

Additive Lipid-Lowering in Combination w/ Statins

Promising Safety and Tolerability

• LDL-C ~30%

• High dose atorvastatin• High dose simvastatin• Digoxin

SafetyEfficacy

• No myalgia as monotherapy• No liver toxicities

• No significant effect on kidney function• No QTc prolongation• No clinically meaningful change in blood pressure• No food effect

No Drug-Drug Interactions

John Kastelein, MD, PhDAmsterdam, Netherlands

Evan Stein, MD, PhDIllinois, USA

Rob Hegele, MDToronto, Canada

Dirk Blom, PhDCape Town, South Africa

Harold Bays, MDKentucky, USA

Peter Toth, MD, PhDIllinois, USA

Jay Horton, MDTexas, USA

David Cohen, MD, PhDNew York, USA

Rohit Loomba, MDCalifornia, USA

Brian Krause, PhDMichigan, USA

Gerald Watts, PhDPerth, Australia

Todd Leff, PhDMichigan, USA

Kevin Williams, MDPennsylvania, USA

Scott Friedman, MDNew York, USA

Key Opinion Leaders in CVD & NASH Drug Development Distinguished Gemphire Advisory Board

29

Dyslipidemia NASH

Mechanism

Lowering LDL-C Decreases CV RiskElevated LDL-C is the #1 Modifiable Risk Factor

Sources: CTT Cholesterol Treatment Trialists and Study Papers for each TrialMACE = Major Adverse Cardiovascular Events* A-Z p=.14 and IDEAL p=.07

Evidence for LDL-C Hypothesis Grows Stronger After March ACCLDL-C Surrogate Endpoint Precedent for Traditional Approval of Lipid Drugs

30

TG

hsCRP

LDL-C Lowering Drugs with Successful Trials: Gemfibrozil: HHS; Atorvastatin: IDEAL, TNT, PROVE-IT, ASCOT-LLA, SPARCL; Rosuvastatin: JUPITER; Simvastatin: A-Z, HPS, 4S; Pravastatin: ALLHAT, CARE, PROSPER, LIPID, WOSCOPS; Lovastatin: AFCAPS; Ezetimibe: IMPROVE-IT

• Over past two decades, all statins and other lipid-lowering drugs, including ezetimibe, were approved on the LDL-C endpoint with broad labels without CV outcomes trial (CVOT) in US and globally

• In US the bar was raised in summer 2015, Praluent approved for HeFH/ASCVD and Repatha approved for HeFH/ASCVD/HoFH on the LDL-C endpoint on maximal tolerated statins; NOT approved for monotherapy (statin-intolerant) and/or primary patients

• In contrast broad labels for Repatha and Praluent were approved on LDL-C endpoint, including monotherapy (statin-intolerant) and primary patients (familial and mixed dyslipidemia) in Europe

At the March ACC meeting, Repatha’s FOURIER CVOT met the primary endpoint for CV risk

reduction, further validating the LDL-C endpoint for regulatory approval in high risk patients

(gemcabene’s ROYAL program)

Repatha

Maximize the Global Commercial Value of GemcabeneDiscussions with Regional and Global Strategic Partners Ongoing

31

Gemphire has retained all global commercial and manufacturing rights to gemcabene

Strategic Partnering

Commercial

HoFH: We may commercialize gemcabene with our own targeted sales force

• 50 lipid centers and 500 lipidologists

SHTG: We may partner or use our sales force and a contract sales force to promote this larger indication

HeFH/ASCVD and NASH: We may partner to commercialize gemcabene in the larger indications

Rest of World We would plan to seek global and regional partners to commercialize in key markets for all indications

Clinical Development

We may consider co-development of gemcabene in Phase 3 for dyslipidemia (CVOT for example)

We may consider co-development of gemcabene in Phase 3 for NASH

Gemcabene Development Program Overview895 Subjects Treated with Gemcabene Across 18 Clinical Trials

32

Low HDL-C and Normal or Elevated TG

Healthy ObeseNon-Diabetic

Hypertension

300, 900 mg(add-on various low, moderate and high intensity statins)

300, 600, 900 mg(concurrent 10, 40, 80 mg atorvastatin)

150, 300, 600, 900 mg

900 mg

900 mg (arm with quinapril 20 mg)

150, 450, 900 mg(arm with rofecoxib 25 mg)

Patient Population: Doses:Trial:

1027-018 n=66 (GEM=42)

1027-014 n=53 (GEM=26)

A4141001n=277 (GEM=208)

1027-012 n=102 (GEM=43)

1027-004n=161 (GEM=129)

A4141004n=404 (GEM=242)

Hypercholesterolemia

12 wks

8 wks

8 wks

4 wks

12 wks

4 wks

4 wks

Completed 11 Phase I Trials in Healthy Volunteers

25 to 1,500 mg

1027-001, -002, -003, -009, -010, -011; A4141003, -005, -006n=163 (GEM=142)

Single and Multiple Dose Studies; Up to 4 wks

Osteoarthritis

Ph

ase

2P

has

e 1

Completed over 30 nonclinical GLP toxicology studies, including: 26-week study in rats and monkeys; 52-week study in monkeys

Ongoing two year carcinogenicity studies in mice and rats

Pre

clin

ical

Duration:

900 mg (DDI Study with 80 mg simvastatin)

15 days

300, 900 mg (DDI Study with 80 mg atorvastatin)

1027-015 n=23 (GEM=23)

A4141002 n=20 (GEM=20)

1027-008 n=20 (GEM=20)

900 mg

22 days

Efficacy Data

Gemcabene Observed to be Well Tolerated in Clinical Trials Adverse Events (AE) Rates Comparable Across All Treatment Groups

• Gemcabene was well tolerated at single doses up to 1500 mg and multiple doses up to 900 mg/day for up to 12 weeks (837 subjects)

• Safety evaluation of AE monitoring, clinical lab assessments, ECGs, physical exams and vital sign assessments were conducted across all trials (1,289 adult subjects):

– 10 healthy volunteers or patients reported a treatment-emergent serious adverse effect (SAE), none of which were related to gemcabene

– No deaths occurred

– AEs were generally mild to moderate (e.g., headache, weakness, nausea)

– No myalgia (muscle effects) as monotherapy, no increase in myalgia when added to statin

– Small mean increases in serum creatinine and blood urea nitrogen (BUN) observed in some trials, reversible within approximately two weeks of cessation of gemcabene

– No clinically meaningful changes in liver enzymes (0.23% of gemcabene patients compared to 0.26% of placebo patients had ALT or AST > 3 times upper limit of normal)

– No clinically meaningful changes were observed in physical examinations, blood pressure, vital signs and ECGs

33